Onconova's myelodysplastic syndrome drug enters Phase III trial

05/12/2013 | Pharmaceutical Business Review Online

Onconova Therapeutics has finished enrolling 270 myelodysplastic syndrome patients for a late-stage trial of rigosertib. The trial will be carried out in the U.S. and five countries in the European Union, with overall survival as main endpoint. The firm expects to release data either in the fourth quarter of this year or the first quarter of next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY